WHOLE BODY AND INTRACRANIAL EFFICACY OF CERITINIB IN ALK-INHIBITOR (ALKi)-NAIVE PATIENTS WITH ALK-REARRANGED (ALK plus ) NSCLC AND BASELINE BRAIN METASTASES (BM): RESULTS FROM ASCEND-1 AND-3

被引：0
|
作者：
Mehra, Ranee [1 ]
Felip, Enriqueta [2 ]
Tan, Daniel Shao-Weng [3 ]
Kim, Dong-Wan [4 ]
Orlov, Sergey [5 ]
Park, Keunchil [6 ]
Yu, Chong-Jen [7 ]
Mok, Tony [8 ]
Nishio, Makoto [9 ]
Scagliotti, Giorgio V. [10 ]
Spigel, David R. [11 ]
Sutradhar, Santosh [12 ]
Cesic, Dajana [12 ]
Shaw, Alice Tsang [13 ]
机构：
[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Vall dHebron Univ, Barcelona, Spain
[3] Natl Canc Ctr, Singapore, Singapore
[4] Seoul Natl Univ Hosp, Seoul, South Korea
[5] St Petersburg State Med Univ, Dept Thorac Oncol, St Petersburg, Russia
[6] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Innovat Canc Med Inst, Seoul, South Korea
[7] Natl Taiwan Univ, Taipei, Taiwan
[8] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[9] Japanese Fdn Canc Res, Tokyo, Japan
[10] Univ Turin, Turin, Italy
[11] Sarah Cannon Res Inst, Nashville, TN USA
[12] Novartis Pharmaceut, E Hanover, NJ USA
[13] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
NEURO-ONCOLOGY | 2016年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
BMET-13
引用
收藏
页码：28 / 29
页数：7
相关论文
共 30 条
  • [21] Brigatinib versus crizotinib in patients with ALK inhibitor-naive advanced ALK plus NSCLC: results from the phase 3 ALTA-1L trial
    Califano, R.
    Camidge, D.
    Kim, H. -R.
    Ahn, M. -J.
    Yang, J.
    Han, J. -Y.
    Hochmair, M.
    Lee, K. H.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D. -W.
    Griesinger, F.
    Felip, E.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Ni, Q.
    Zhang, P.
    Popat, S.
    LUNG CANCER, 2020, 139 : S59 - S60
  • [22] Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
    Crino, Lucio
    Ahn, Myung-Ju
    De Marinis, Filippo
    Groen, Harry J. M.
    Wakelee, Heather
    Hida, Toyoaki
    Mok, Tony
    Spigel, David
    Felip, Enriqueta
    Nishio, Makoto
    Scagliotti, Giorgio
    Branle, Fabrice
    Emeremni, Chetachi
    Quadrigli, Massimiliano
    Zhang, Jie
    Shaw, Alice T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (24) : 2866 - +
  • [23] Updated Results from the Phase 3 ALTA-1L Trial of Brigatinib (BRG) vs. Crizotinib (CRZ) in ALK Inhibitor-Naive Advanced ALK plus NSCLC
    Griesinger, Frank
    Camidge, D. Ross
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James Chih-Hsin
    Han, Ji Youn
    Hochmair, Maximilian
    Lee, Hyeong
    Delmonte, Angelo
    Garcia Compelo, Maria Rosario
    Kim, Dong-Wan
    Felip, Enriqueta
    Califano, Raffaele
    Spire, Alexander
    Gettinger, Scott N.
    Tiseo, Marcello
    Lin, Huamao M.
    Ni, Quanhong
    Zhang, Pingkuan
    Popat, Sanjay
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 232 - 232
  • [24] Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study
    Scagliotti, G.
    Kim, T. M.
    Crino, L.
    Liu, G.
    Gridelli, C.
    Novello, S.
    Kiura, K.
    Bearz, A.
    Gautschi, O.
    Felip, E.
    Nishio, M.
    Spigel, D. R.
    Mok, T. S. K.
    Urban, P.
    Deudon, S.
    Zheng, C.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [25] A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK plus NSCLC) patients (pts): Updates on progression free survival (PFS) and safety results from AF-001JP.
    Ohe, Yuichiro
    Nishio, Makoto
    Kiura, Katsuyuki
    Seto, Takashi
    Nakagawa, Kazuhiko
    Maemondo, Makoto
    Inoue, Akira
    Hida, Toyoaki
    Yoshioka, Hiroshige
    Harada, Masao
    Nogami, Naoyuki
    Murakami, Haruyasu
    Takeuchi, Kengo
    Shimada, Tadashi
    Kuriki, Hiroshi
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LW: Results from the phase II, ASCEND-7 study
    Barlesi, F.
    Kim, D. -W.
    Bertino, E. M.
    van den Bent, M. J.
    Wakelee, H.
    Wen, P. Y.
    Garrido Lopez, P.
    Orlov, S.
    Majem, M.
    McKeage, M.
    Yu, C. -J.
    Hurtado, F. K.
    Arratia, P. Cazorla
    Song, Y.
    Branle, F.
    Shi, M.
    Chow, L. Q.
    ANNALS OF ONCOLOGY, 2019, 30 : 143 - +
  • [27] Activity and safety of ceritinib in patients with ALK-rearranged non- small- cell lung cancer (ASCEND- 1): updated results from the multicentre, open-label, phase 1 trial (vol 17, pg 452, 2016)
    Kim, D-W
    Mehra, R.
    Tan, D. S. W.
    LANCET ONCOLOGY, 2016, 17 (05): : E181 - E181
  • [28] Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naive Patients with ALK plus Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis
    Cho, Byoung Chul
    Kim, Dong-Wan
    Batra, Ullas
    Park, Keunchil
    Kim, Sang -We
    Yang, Cheng-Ta
    Voon, Pei-Jye
    Sriuranpong, Virote
    Babu, K. Govind
    Amin, Khalid
    Wang, Yingbo
    Sen, Paramita
    Slimane, Khemaies
    Geater, Sarayut
    CANCER RESEARCH AND TREATMENT, 2023, 55 (01): : 83 - 93
  • [29] Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK plus Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
    Ahn, Myung J.
    Kim, Hye R.
    Yang, James C. H.
    Han, Ji-Yu
    Li, Jacky Yu-Chung
    Hochmair, Maximilian J.
    Chang, Gee-Chen
    Delmonte, Angelo
    Lee, Ki H.
    Campelo, Rosario G.
    Gridelli, Cesare
    Spira, Alexander, I
    Califano, Raffaele
    Griesinger, Frank
    Ghosh, Sharmistha
    Felip, Enriqueta
    Kim, Dong-Wan
    Liu, Yuyin
    Zhang, Pingkuan
    Popat, Sanjay
    Camidge, D. Ross
    CLINICAL LUNG CANCER, 2022, 23 (08) : 720 - 730
  • [30] Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
    Gadgeel, Shirish M.
    Gandhi, Leena
    Riely, Gregory J.
    Chiappori, Alberto A.
    West, Howard L.
    Azada, Michele C.
    Morcos, Peter N.
    Lee, Ruey-Min
    Garcia, Linta
    Yu, Li
    Boisserie, Frederic
    Di Laurenzio, Laura
    Golding, Sophie
    Sato, Jotaro
    Yokoyama, Shumpei
    Tanaka, Tomohiro
    Ou, Sai-Hong Ignatius
    LANCET ONCOLOGY, 2014, 15 (10): : 1119 - 1128
123